These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 120167)

  • 41. Vaccines and immunotherapy against Pseudomonas aeruginosa.
    Döring G; Pier GB
    Vaccine; 2008 Feb; 26(8):1011-24. PubMed ID: 18242792
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The epidemiology of Pseudomonas aeruginosa and the development of a polyvalent vaccine.
    Pranter W; Staerk J; Zellner R; Zwisler O
    Prog Immunobiol Stand; 1971; 5():414-8. PubMed ID: 4633968
    [No Abstract]   [Full Text] [Related]  

  • 43. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
    Pier G
    Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunoprophylaxis of Pseudomonas aeruginosa.
    Young LS; Armstrong D; Markley K
    Ann Intern Med; 1971 Jun; 74(6):1012-3. PubMed ID: 4996343
    [No Abstract]   [Full Text] [Related]  

  • 45. Vaccines against Pseudomonas aeruginosa results and perspectives of investigations (survey).
    Joó I; Stanislavskii ES
    J Hyg Epidemiol Microbiol Immunol; 1982; 26(4):417-27. PubMed ID: 6819316
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preparation and assay of horse anti-Pseudomonas serum and -globulin in mice.
    Laborde HF; De Fajardo CL
    Prog Immunobiol Stand; 1971; 5():419-24. PubMed ID: 4633969
    [No Abstract]   [Full Text] [Related]  

  • 47. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
    Zaidi TS; Priebe GP; Pier GB
    Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Active immunization of burned patients with a new multivalent Staphylococcus-Pseudomonas vaccine.
    Sachs A
    Prog Immunobiol Stand; 1971; 5():428-32. PubMed ID: 4633971
    [No Abstract]   [Full Text] [Related]  

  • 49. Mouse-protection experience with monovalent Pseudomonas aeruginosa vaccine.
    Sourek J; Výmola F; Zelenková L
    Zentralbl Bakteriol A; 1980 Mar; 246(3):353-62. PubMed ID: 6775443
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A polyvalent Pseudomonas vaccine.
    Sato H; Diena BB
    Rev Can Biol; 1974 Jun; 33(2):93-7. PubMed ID: 4211759
    [No Abstract]   [Full Text] [Related]  

  • 51. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine].
    Schiller B; Lysakowska E; Owczarska K
    Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849
    [No Abstract]   [Full Text] [Related]  

  • 52. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections.
    Baumann U; Mansouri E; von Specht BU
    Vaccine; 2004 Feb; 22(7):840-7. PubMed ID: 15040936
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Conjugate vaccines against Pseudomonas aeruginosa and malaria.
    Cryz SJ; Sadoff JC; Que JU
    Contrib Microbiol Immunol; 1989; 10():166-89. PubMed ID: 2510972
    [No Abstract]   [Full Text] [Related]  

  • 54. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
    Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
    APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Determination of type specific IgG Pseudomonas antibodies by the ELISA test after administration of the anti Pseudomonas aeruginosa vaccine.
    Meitert T; Meitert E; Pencu E; Tonciu M
    Arch Roum Pathol Exp Microbiol; 1984; 43(1):53-60. PubMed ID: 6442132
    [No Abstract]   [Full Text] [Related]  

  • 56. The protective role of pulmonary neutrophils in rats intestinally immunized with Pseudomonas aeruginosa.
    Buret A; Dunkley M; Clancy RL; Cripps AW
    Adv Exp Med Biol; 1995; 371B():765-9. PubMed ID: 7502894
    [No Abstract]   [Full Text] [Related]  

  • 57. Investigations on the efficacy of monovalent Pseudomonas aeruginosa vaccine for oral administration in Pseudomonas aeruginosa experimental infection.
    Meitert E; Sima F; Savulian C; Petrovici M; Chersulick E; Costache G
    Arch Roum Pathol Exp Microbiol; 1989; 48(3):237-51. PubMed ID: 2519634
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A new polyvalent Pseudomonas vaccine.
    Miler JM; Spilsbury JF; Jones RJ; Roe EA; Lowbury EJ
    J Med Microbiol; 1977 Feb; 10(1):19-27. PubMed ID: 402473
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Combined Staphylococcus-Proteus-Pseudomonas vaccine. I. Effectiveness of the vaccine in experimental Pseudomonas aeruginosa infections].
    Stanislavskiĭ ES; Kreĭnin LS; Egorova NB; Kaverina KG; Efremova VN
    Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):57-61. PubMed ID: 7331610
    [No Abstract]   [Full Text] [Related]  

  • 60. Molluscan immunity: induction of elevated immunity in the land snail (Helix) by injections of bacteria (Pseudomonas aeruginosa).
    Bayne CJ
    Dev Comp Immunol; 1980; 4(1):43-54. PubMed ID: 6768603
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.